Drug Trial Radar · NCT05577416
A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma
Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14
Actual
Start
Oct 11, 2022
Primary completion
Mar 26, 2025
Study completion Mar 26, 2025
Sponsor
- Lead sponsor
- Melbourne HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Walter and Eliza Hall Institute of Medical Research; Nuvation Bio Inc.
- First posted
- Oct 13, 2022
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this clinical trial is to evaluate the feasibility of undertaking a Phase 0 surgical study in patients with diagnosis of a IDH1 mutated Low Grade Glioma (LGG) who have not received prior radiation or chemotherapy and are planned to undergo surgical resection.
Conditions
- Glioma
Interventions
BiopsyProcedure
Patients will undergo stereotactic biopsy by craniotomy or burr hole.
Part A: Safusidenib ErbumineDrug
Part A: Safusidenib Erbumine orally 250 mg BID for 28 days.
Surgery (maximal resection)Procedure
Surgery: Maximal safe resection, within 24 hours of last dose of Safusidenib Erbumine.
Part B: Safusidenib ErbumineDrug
Part B: Safusidenib Erbumine orally 250 mg BID for 28 days for a minimum of 12, 28-day cycles subject to ongoing documented evidence of clinical benefit, until disease progression or unacceptable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 0: Feasibility of Phase 0 study in patient populationTime frame: 14 months
- Phase 0: pharmacokinetic analysis of tumour tissueTime frame: 4 weeks
- Phase 0: pharmacokinetic analysis of cerebrospinal fluid (CSF)Time frame: 4 weeks
- Phase 2: Number of Adverse eventsTime frame: up to 30 days after last study dose
- Phase 2: Incidence of drug related adverse eventsTime frame: up to 30 days after last study dose
- Phase 2: Incidence of dose limiting toxicityTime frame: up to 30 days after last study dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Royal Melbourne Hospital
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.